Aegean in the clear
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
An adcom on Imfinzi’s Aegean trial will show whether neoadjuvant and adjuvant benefits must be split out.
The FDA throws out the company’s second attempt at an accelerated approval.
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.